Dizziness Often Occurred Before the Final Target Dose in the Parkinson Cannabinoid Trial
Most dizziness reports in the Parkinson trial occurred below the final protocol dose. The adverse-event pattern did not support describing lower titration doses as free of symptoms.
The timing and dose context were recorded
Dizziness was the most common adverse effect in the CBD/THC group. Most reports were mild, and approximately 80.6% occurred at doses below the final 2.5-milligram-per-kilogram daily regimen as defined by the study. Adverse events were more common at the initial than final dose assessment.
This was not a randomized dose-safety comparison
Participants could reduce doses for tolerability, and thirteen active-treatment participants did not reach a protocol dose. Those who tolerated early treatment could therefore differ from those who reduced it. The pattern cannot establish that the higher dose was intrinsically safer or that symptoms necessarily resolved through tolerance.
Titration does not eliminate functional questions
Calling an event mild describes its severity category, not an absence of potential effects on balance or daily activities. The trial also found no overall motor superiority over placebo. A balanced interpretation retains when symptoms occurred, which participants achieved the target and the limited duration of exposure. It does not turn a later lower event frequency into a guarantee about either dose for a particular patient.
Related analysis: the study’s broader findings and limitations.
